Allergic rhinitis is a common disease characterized by the
|
|
- Lynne Garrison
- 5 years ago
- Views:
Transcription
1 Comparison of antileukotrienes and antihistamines in the treatment of allergic rhinitis Ching-Yin Ho,* M.D., Ph.D., and Ching-Ting Tan,# M.D., Ph.D. (Taiwan) ABSTRACT Background: The aim of this study was to compare the effect of antileukotriene (anti-lt), antihistamine, and a combination of anti-lt and antihistamine on the symptoms and nasal resistance in allergic rhinitis patients. Methods: We performed a placebo-controlled study, with 120 persistent, moderate to severe allergic rhinitis patients randomly selected to receive the different treatments for 4 weeks: no treatment, 10 mg of cetirizine once per day, 20 mg of zafirlukast once per day, 20 mg of zafirlukast twice per day, a combination of 20 mg of zafirlukast and 10 mg of cetirizine once per day, or a combination of 20 mg of zafirlukast twice per day and 10 mg cetirizine once per day. The nasal secretion nitric oxide (NO) concentration, nasal symptom score, and nasal resistance were measured before and after treatment. Results: Total symptom scores improved in each treated group compared with the control group (p 0.05). Nasal obstruction significantly improved in the anti-lt treated groups (p 0.05). High-dose anti-lt or the combination of low-dose anti-lt and antihistamine significantly improved allergy symptoms compared with no treatment, low-dose anti-lt, or antihistamine alone (p 0.05). Furthermore, anti-lt decreased NO concentration in nasal secretions (p 0.05), regardless of the dose administered. Conclusion: These results suggest that high-dose anti-lt alone or the combination of low-dose anti-ly and antihistamine can effectively treat allergic rhinitis. (Am J Rhinol 21, , 2007; doi: /ajr ) Key words: Allergic rhinitis, anterior rhinomanometry, antihistamine, antileukotriene, asthma, cetirizine, nasal resistance, nitric oxide, zafirlukast Allergic rhinitis is a common disease characterized by the infiltration of inflammatory cells into the nasal mucosa. 1,2 Two of the most abundant and potent mediators are histamine and cysteinyl leukotrienes (LTs). 3,4 Histamine has long been implicated as a major mediator of allergic rhinitis, primarily causing sneezing, nasal itching, and rhinorrhea. In contrast to histamine, LTs such as LTC 4 and LTD 4 contribute to vascular permeability and vasodilation resulting in mucosal swelling, which causes rhinorrhea and nasal congestion. 5 7 In addition, the nasal allergen challenge-induced release of cysteinyl LTs has been correlated with allergic symptoms Furthermore, nasal congestion in the early phase and the late phase is accompanied by a significant increase of cysteinyl LTs in nasal lavage fluid from allergic rhinitis patients. 9 Therefore, it is indicated that cysteinyl LTs play an important role in allergic rhinitis. Studies support the possibility that nitric oxide (NO) plays an important role in regulating nasal functions Recent studies in rats showed that the increased vascular permeability induced by a histamine nasal challenge can be blocked by perfusion with an NO synthase (NOS) inhibitor in the nasal cavity contralateral to nasal challenge. 12,13 A rabbit study From the *Department of Otolaryngology, Veterans General Hospital-Taipei and National Yang-Ming University, Taipei, Taiwan, and #Department of Otolaryngology, National Taiwan University Hospital and National Taiwan University College of Medicine Taipei, Taiwan Supported by Grant NSC B from the National Science Council, Grants VGH and VGH from the Veterans General Hospital Taipei, and Grants NTUH 92-N005 and NTUH 93-S034 Address correspondence and reprint requests to Ching-Yin Ho, M.D., Ph.D., Department of Otolaryngology, Veterans General Hospital Taipei. Number 201, Section 2, Shih-Pai Road, Taipei 112, Taiwan address: cyho@vghtpe.gov.tw Copyright 2007, OceanSide Publications, Inc., U.S.A. showed that the nasal application of sodium nitroprusside, an NO donor, increased ciliary beat frequency in vitro and mucociliary activity in vivo. 15,16 The same nasal application of an NO donor also has been shown to increase the mucociliary activity and blood flow in human nasal mucosa. These findings indicated that NO plays an important role in the regulation of vascular permeability, mucociliary activity, and blood flow in nasal mucosa. An elevated level of NO in nasalexhaled air has been found in patients with allergic rhinitis; this elevation decreased after treatment with steroid nasal spray or antihistamine However, the relationship between the NO concentration in the nasal secretion and anti-lt effect remains unknown. This study was conducted for two purposes. First, we designed a randomized trial to compare the effect of anti-lt, antihistamine, and a combination of anti-lt and antihistamine on the symptoms of allergic rhinitis and also on nasal resistance measured by active anterior rhinomanometry (AAR). Second, we investigated the concentration of nasal secretion of NO in the allergic rhinitis patients treated with anti-lt, antihistamine, or a combination of both. MATERIALS AND METHODS This study was approved by the Committee of Clinical Research Studies at the Veterans General Hospital-Taipei. All patients were told the aim of the study, after which each patient provided written informed consent. Patients and Study Design Patients eligible for this study were healthy adult men and women who had a clinical history of allergic rhinitis for at least 2 years and who tested positive only for mite allergy in the multiple allergen simultaneous test. All patients suffered from persistent, moderate to severe allergies according to the American Journal of Rhinology 439
2 classification of Allergic Rhinitis and Its Impact on Asthma. 20 Patients were excluded if they had any chronic nasal diseases or if they had received corticosteroid nasal spray, oral antihistamine, oral decongestant, or oral corticosteroids in the past 3 months. During a 7-day lead-in period, baseline nasal resistance and NO concentration of the nasal secretions were obtained and diary card assessments were performed on 120 adult allergic rhinitis patients. Then, these patients were randomly selected to receive one of the following six treatments for 4 weeks: no treatment (P group), 10 mg of cetirizine once per day (C group), 20 mg of zafirlukast once per day (Z20 group), 20 mg of zafirlukast twice per day (Z40 group), a combination of 20 mg of zafirlukast and 10 mg of cetirizine once per day (Z20 C group), or a combination of 20 mg of zafirlukast twice per day and 10 mg of cetirizine once per day (Z40 C group). After 4 weeks, the nasal resistance was measured, as well as the NO concentration in the nasal secretions, and the diary card assessments were recorded again. Symptom Scale Score Subjective assessment of nasal symptoms was conducted before and throughout the study; patients assessed their subjective sensations of sneezing, rhinorrhea, and nasal obstruction. Symptoms were graded on a scale of 0 10, with 0 representing no perceived symptoms and 10 representing the greatest severity of symptoms imaginable. This assessment was made both at baseline and after treatment. Measurement of Nasal Resistance Measurements of nasal resistance were made using a Mercury Electronics NR6 rhinomanometry (Instrument Rhinomanometry NR6 2 G. M. Instruments, Ltd., U.K.) for AAR. This rhinomanometry measured the nasal flow rate during tidal breathing, while simultaneously measuring the nasopharyngeal pressure that produced the flow. Airflow was measured using a face mask with a pneumotachograph positioned at the inlet. An integral nasal cannula for measuring nasopharyngeal pressure was placed in the subject s nasal cavity and sealed with the tape. The face mask was placed firmly on the face and the airflow was measured through the other nasal cavity. Inspiration and expiration were measured separately. AAR resistance was measured separately for each side of the nose and the total resistance was calculated by the computer program. Collection of Nasal Secretion A microsuction system, which was designed by the investigators, was used to collect nasal secretions. The applied pressure was 0.04 MPa ( 408 cm H 2 O). Under the rigid scope, we put the suction into patients nasal cavities and aspirated all secretion in the nasal cavity. Nasal fluid was stored on ice and centrifuged for 10 minutes at 1000 g. The supernatant was stored at 80 C until analysis. Concentrations of NO in the nasal secretions were measured using HPLC. Measurement of NO 2 and NO 3 Levels NO 2 and NO 3 levels in the nasal secretions were separated by a reverse-phase separation column packed with polystyrene polymer (NO-PAK, mm; Eicom, Kyoto, Japan), and NO 3 was reduced to NO 2 in a reduction column packed with copper-plated cadmium filings (NO-RED; Eicom). NO 2 was mixed with a Griess reagent to form purple azo dye I in a reaction coil. The separation and reduction columns and the reaction coil were placed in a column oven that was set at 35 C. The absorbance of the product dye at 540 nm was measured by a flow-through spectrophotometer (NOD-20; Eicom). The mobile phase, which was delivered by a pump at a rate of 0.33 ml/minute, was 10% methanol containing 0.15 M of NaCl/NH 4 Cl and 0.5 g/l of 4Na-EDTA. The Griess reagent, which was 1.25% HCl containing 5 g/l of sulfanilamide with 0.25 g/l of N-naphthlenediamine, was delivered at a rate of 0.1 ml/minute. The contamination of NO 2 and NO 3 in Ringer s solution and the reliability of the reduction column were examined in each experiment. Data and Statistical Analysis All results were analyzed by one-way analysis of variance, which was adjusted for multiple comparison by Duncan s method when appropriate. The value of p 0.05 was considered significant. All data are presented as means SE. RESULTS One hundred twenty allergic rhinitis patients were included in this study. The male-to-female ratio was 74:46, and their ages ranged from 18 to 68 years. Before treatment, the symptom score, nasal resistance, and NO concentration of nasal secretion showed no significant differences between each group. The total symptom score improved after treatment in the treated group (p 0.05; Fig. 1 A). The high-dose anti-lt alone (Z40) and the combination of anti-lt, including low- and high-dose, and antihistamine (Z20 C and Z40 C) caused better results than the low-dose anti-lt (Z20) or antihistamine (C) alone (Fig. 1 A). In the C group, the symptoms of sneezing and rhinorrhea improved significantly (Fig. 1, C and D), but nasal obstruction did not improve (Fig. 1 B). In the Z20 group, rhinorrhea improved, but sneezing and nasal obstruction did not (Fig. 1, B D). All allergic symptoms, including sneezing, rhinorrhea, and nasal obstruction, were significantly reduced after Z40, Z20 C or Z40 C treatment; however, the treatment effect was similar in Z40, Z20 C, and Z40 C groups (Fig. 1, B D). The objective nasal resistance was measured via AAR before and after treatment. Both the P group and the C group showed no change after treatment. Nasal resistance significantly decreased in patients who received Z40, Z20 C, and Z40 C treatment. Nasal resistance did not show significant difference between the Z40, Z20 C, and Z40 C groups (Fig. 2). The baseline nasal NOx concentration was pmol, pmol, pmol, pmol, pmol, and pmol in the P, C, Z20, Z40, Z20 C, and Z40 C groups, respectively, and there was no difference in any of the groups (Fig 3). After treatment, the NOx concentration in nasal secretions did not change in the group receiving antihistamine alone (Fig. 3). However, the concentration of NOx in nasal secretions significantly decreased after anti-lt treatment in either low or high doses. The addition of antihistamine to either low- or high-dose zafirlukast did not further reduce the concentration of NOx (Fig. 3). 440 July August 2007, Vol. 21, No. 4
3 Figure 1. Symptom score of allergic rhinitis before and after treatment. (A) Total symptom score; (B) nasal obstruction score; (C) sneezing score; (D) rhinorrhea score. *, Significantly different from before treatment; a, significantly different from the posttreatment of C group; b, significantly different from the posttreatment of Z20 group; P, no treatment; C, 10 mg of cetirizine once per day; Z20, 20 mg of zafirlukast once per day; Z40, 20 mg of zafirlukast twice per day; Z20 C, a combination of 20 mg of zafirlukast and 10 mg of cetirizine once per day; Z40 C, a combination of 20 mg of zafirlukast twice per day and 10 mg of cetirizine once per day (p 0.05 was considered significant). DISCUSSION Our results show that the combination of anti-lt and antihistamine improved nasal allergic symptoms significantly compared with treatments of placebo, antihistamine, or low doses of anti-lt alone. Not only did the subjective symptom score improve, but also the objective nasal resistance decreased. In addition, anti-lt decreased the NO concentration in the nasal secretions regardless of the dose administered and regardless of an additional antihistamine. The levels of histamine and cysteinyl LTs were elevated in the nasal secretion of patients with allergic rhinitis when triggered by IgE-mediated reactions. 10 In addition, the release of histamine and LTs contributes to the allergic nasal symptoms by exerting selective effects in the nose. 21,22 Histamine nasal challenge induces neurological responses, such as itching and sneezing, but affects nasal congestion to a lesser degree. Therefore, LTs contribute to the pathophysiology of allergic rhinitis and potentially increase both mucus production and congestion. One recent study examined the possible advantages of a combination of anti-lt and antihistamine for asthma. 23 That study showed that the concomitant use of loratadine and zafirlukast was significantly more effective in diminishing the response to an inhaled allergen challenge than the use of loratadine or zafirlukast alone. Both histamine and LT receptor antagonists have antiallergic and anti-inflammatory properties, including effects on mediator release and the chemoattraction of inflammatory cells. These findings suggested that administering antihistamine and LT modifiers together might result in an amplified effect in the treatment of allergic rhinitis. Our results indicated that sneezing and rhinorrhea significantly improved in C-group patients but no significant change was observed in nasal obstruction, which profoundly affects the nasal obstruction symptom score and nasal resistance. The Z20-group patients improved only in nasal obstruction, and no change was observed in rhinorrhea and sneezing. The Z40, Z20 C, and Z40 C groups showed significant improvement in all allergic nasal symptoms, including sneezing, rhinorrhea, and nasal obstruction, with no difference between each group. This result shows that either high-dose anti-lt or a combination of low-dose anti-lt and antihistamine has the same effect on allergic rhinitis patients. Therefore, the combination of low-dose anti-lt and antihistamine or the use of high-dose anti-lt alone is a good treatment choice for allergic rhinitis patients. As shown in an earlier study, LTD 4 is 5000 times more potent than histamine in inducing increased nasal airway resistance in humans. 24 It is noteworthy that this increase is more prolonged than that induced by histamine and is similar to that induced by antigens. In recent animal studies, nasal LTD 4 challenge was shown to increase nasal airway resistance, 25 and anti-lt can inhibit the antigen-induced increase in nasal resistance. 26 Our results show that both a low dose or high dose of anti-lt, with or without additional antihistamine, can improve subjective nasal obstruction and objective nasal resistance. These results indicate that anti-lts are more powerful in the improvement of nasal congestion than the new generation antihistamine in allergic rhinitis. The relationship between NO and chronic allergic responses has been emphasized, because NO acts as a powerful mediator involved in several atopic diseases. 27 For example, American Journal of Rhinology 441
4 the function of NO in the nasal mucosa related to the allergic reaction. Kharitonov et al. 31 recently found that nasal NO levels were significantly elevated in patients with untreated rhinitis compared with normal individuals or subjects treated with topical steroids. The previous results showed that the degree of inducible NOS expression by epithelial cells was significantly elevated in an allergic rhinitis group compared with that of the control group. 32 However, the relationship between LTC and NO in allergic rhinitis was not clear. Our study showed that both low-dose or high-dose anti-lt treatment decreased the NO concentration in the nasal secretions of allergic rhinitis patients. Our results also showed that anti- LT significantly improves nasal obstruction and decreases nasal resistance. Therefore, the mechanism of anti-lt may improve nasal congestion by inhibiting NO formation. Figure 2. Total nasal resistance of allergic rhinitis patients before and after treatment, measured by anterior rhinomanometry. (A) Left nasal resistance; (B) right nasal resistance. *, Significantly different from before treatment; a, significantly different from the posttreatment of C group (p 0.05 was considered significant. The grouping was the same as in Fig. 1. Figure 3. NOx concentration of nasal secretion in allergic rhinitis before and after treatment. *, Significantly different from before treatment; a, significantly different from the posttreatment of P group (p 0.05 was considered significant). The grouping was the same as in Fig. 1. patients with bronchial asthma have shown elevated NO levels in exhaled air. 28,29 Hamid et al. 30 reported an increased expression of NOS, which is an enzyme responsible for NO production, in bronchial epithelial cells from untreated asthmatic patients, and suggested its relevance to the pathology of asthma. In contrast to the lower airways, little is known about CONCLUSION High-dose anti-lt, a combination of low-dose anti-lt and antihistamine, or a combination of high-dose anti-lt and antihistamine produce the same treatment results in allergic rhinitis patients, including improved nasal allergic symptoms and nasal resistance, and decreased NO concentrations in nasal secretions. Therefore, our results indicate that two good treatment choices for allergic rhinitis patients are either the combination of low-dose anti-lt and antihistamine or the use of high-dose anti-lt alone. REFERENCES 1. Baraniuk JN. Pathogenesis of allergic rhinitis. J Allergy Clin Immunol 99:S763 S772, Bascom R, Pipkorn U, Lichtenstein LM, et al. The influx of inflammatory cells into nasal washings during the late response to antigen challenge. Effect of systemic steroid pretreatment. Am Rev Respir Dis 138: , Miadonna A, Tedeschi A, Leggieri E, et al. Behavior and clinical relevance of histamine and leukotrienes C4 and B4 in grass pollen-induced rhinitis. Am Rev Respir Dis 136: , Creticos PS, Peters SP, Adkinson NF Jr, et al. Peptide leukotriene release after antigen challenge in patients sensitive to ragweed. N Engl J Med 310: , Howarth PH. Leukotrienes in rhinitis. Am J Respir Crit Care Med 161:S133 S136, Simon RA. The role of leukotrienes and antileukotriene agents in the pathogenesis and treatment of allergic rhinitis. Clin Rev Allergy Immunol 17: , Busse W, and Kraft M. Cysteinyl leukotrienes in allergic inflammation: Strategic target for therapy. Chest 127: , Peters-Golden M, and Henderson WR Jr. The role of leukotrienes in allergic rhinitis. Ann Allergy Asthma Immunol 94: , Naclerio RM, Baroody FM, and Togias AG. The role of leukotrienes in allergic rhinitis: A review. Am Rev Respir Dis 143:S91 S95, Saito H, Morikawa H, Howie K, et al. Effects of a cysteinyl leukotriene receptor antagonist on eosinophil recruitment in experimental allergic rhinitis. Immunology 113: , Ferguson EA, and Eccles R. Relationship between nasal nitric oxide concentration and nasal airway resistance. Rhinology 35: , July August 2007, Vol. 21, No. 4
5 12. Lane AP, Prazma J, Gibbons PJ, et al. The role of nitric oxide in the neural control of nasal fluid production. Am J Rhinol 11: , Lane AP, Prazma J, Baggett HC, et al. Nitric oxide is a mediator of neurogenic vascular exudation in the nose. Otolaryngol Head Neck Surg 116: , Alberty J, August C, Stoll W, et al. The effect of endogenous nitric oxide on cholinergic ciliary stimulation of human nasal mucosa. Laryngoscope 114: , Imada M, Nonaka S, Kobayashi Y, et al. Functional roles of nasal nitric oxide in nasal patency and mucociliary function. Acta Otolaryngol 122: , Kim JW, Min YG, Rhee CS, et al. Regulation of mucociliary motility by nitric oxide and expression of nitric oxide synthase in the human sinus epithelial cells. Laryngoscope 111: , Vural C, and Gungor A. The effect of topical fluticasone on nasal nitric oxide levels in a patient with allergic rhinitis. Ear Nose Throat J 82: , Gratziou C, Rovina N, Lignos M, et al. Exhaled nitric oxide in seasonal allergic rhinitis: Influence of pollen season and therapy. Clin Exp Allergy 31: , Wilson AM, Dempsey OJ, Sims EJ, et al. Subjective and objective markers of treatment response in patients with seasonal allergic rhinitis. Ann Allergy Asthma Immunol 85: , Bousquet J, Van CP, and Khaltaev N. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol 108:S147 S334, Naclerio RM. Allergic rhinitis. N Engl J Med 325: , Meltzer EO. Role for cysteinyl leukotriene receptor antagonist therapy in asthma and their potential role in allergic rhinitis based on the concept of one linked airway disease. Ann Allergy Asthma Immunol 84: , Roquet A, Dahlen B, Kumlin M, et al. Combined antagonism of leukotrienes and histamine produces predominant inhibition of allergen-induced early and late phase airway obstruction in asthmatics. Am J Respir Crit Care Med 155: , White MV, and Kaliner MA. Mediators of allergic rhinitis. J Allergy Clin Immunol 90: , Fujita M, Nakagawa N, Yonetomi YT, et al. Cysteinyl leukotrienes induce nasal symptoms of allergic rhinitis via a receptor-mediated mechanism in guinea pigs. Jpn J Pharmacol 75: , Fujita M, Yonetomi Y, Shimouchi K, et al. Involvement of cysteinyl leukotrienes in biphasic increase of nasal airway resistance of antigen-induced rhinitis in guinea pigs. Eur J Pharmacol 369: , Kharitonov SA, Yates D, Robbins RA, et al. Increased nitric oxide in exhaled air of asthmatic patients. Lancet 343: , Gill M, Walker S, Khan A, et al. Exhaled nitric oxide levels during acute asthma exacerbation. Acad Emerg Med 12: , Taylor DR. Nitric oxide as a clinical guide for asthma management. J Allergy Clin Immunol 117: , Hamid Q, Springall DR, Riveros-Moreno V, et al. Induction of nitric oxide synthase in asthma. Lancet 342: , Kharitonov SA, Rajakulasingam K, O Connor B, et al. Nasal nitric oxide is increased in patients with asthma and allergic rhinitis and may be modulated by nasal glucocorticoids. J Allergy Clin Immunol 99:58 64, Kawamoto H, Takeno S, and Yajin K. Increased expression of inducible nitric oxide synthase in nasal epithelial cells in patients with allergic rhinitis. Laryngoscope 109: , e American Journal of Rhinology 443
British Journal of Clinical Pharmacology
et al. et al. British Journal of Clinical Pharmacology DOI:10.1111/j.1365-2125.2004.02072.x Effects of single or combined histamine H 1 -receptor and leukotriene CysLT 1 -receptor antagonism on nasal adenosine
More informationThe role of histamine in allergic rhinitis
The role of histamine in allergic rhinitis Robert M. Naclerio, MD Baltimore, Maryland Studies using nasal provocation followed by nasal lavage have demonstrated that histamine plays a n important role
More informationALLERGIC RHINITIS AND ASTHMA :
ALLERGIC RHINITIS AND ASTHMA : from the Link to Emerging Therapies Allergic rhinitis and asthma are both chronic heterogeneous disorders, with an overlapping epidemiology of prevalence, health care costs
More informationAllergic Rhinitis. Abstract Allergic rhinitis is defined as an immunologic response moderated by IgE and is. Continuing Education Column
Allergic Rhinitis Hun Jong Dhong, M.D. Department of Otorhinolaryngology Head and Neck Surgery Sungkyunkwan University School of Medicine, Samsung Medical Center E mail : hjdhong@smc.samsung.co.kr Abstract
More informationImplications on therapy. Prof. of Medicine and Allergy Faculty of Medicine, Cairo University
Implications on therapy Dr. Hisham Tarraf MD,FRCP(Edinb.) Prof. of Medicine and Allergy Faculty of Medicine, Cairo University Need for better understanding Global health problem Impact on quality of life
More informationPhototherapy in Allergic Rhinitis
Phototherapy in Allergic Rhinitis Rhinology Chair KSU KAUH Ibrahim AlAwadh 18\1\2017 MBBS, SB & KSUF Resident, ORL-H&N Background: Endonasal phototherapy can relieve the symptoms of allergic rhinitis
More informationHow immunology informs the design of immunotherapeutics.
How immunology informs the design of immunotherapeutics. Stephen R Durham Allergy and Clinical Immunology, Royal Brompton Hospital and Imperial College London WAO Cancun Mon Dec 5 th 2011 How immunology
More informationDerriford Hospital. Peninsula Medical School
Asthma and Allergic Rhinitis iti What is the Connection? Hisham Khalil Consultant ENT Surgeon Clinical Senior Lecturer, PMS Clinical Sub-Dean GP Evening 25 June 2008 Plymouth Derriford Hospital Peninsula
More informationImmunology of Asthma. Kenneth J. Goodrum,Ph. Ph.D. Ohio University College of Osteopathic Medicine
Immunology of Asthma Kenneth J. Goodrum,Ph Ph.D. Ohio University College of Osteopathic Medicine Outline! Consensus characteristics! Allergens:role in asthma! Immune/inflammatory basis! Genetic basis!
More informationE-1 Role of IgE and IgE receptors in allergic airway inflammation and remodeling
E-1 Role of IgE and IgE receptors in allergic airway inflammation and remodeling Ruby Pawankar, MD, Ph.D. FRCP, FAAAAI Prof. Div of Allergy, Dept of Pediatrics Nippon Medical School Tokyo, Japan pawankar.ruby@gmail.com
More informationFunction of the Respiratory System. Exchange CO2 (on expiration) for O2 (on inspiration)
Function of the Respiratory System Exchange CO2 (on expiration) for O2 (on inspiration) Upper Respiratory Tract Includes: Nose Mouth Pharynx Larynx Function: Warms and humidifies the inspired air Filters
More informationALLERGIC RHINITIS Eve Kerr, M.D., M.P.H.
- 63-3. ALLERGIC RHINITIS Eve Kerr, M.D., M.P.H. We conducted a MEDLINE search of review articles on rhinitis between the years of 1990-1995 and selected articles pertaining to allergic rhinitis. We also
More informationExpired nitric oxide levels in adult asthmatics
Allergology International (1996) 45: 85-89 Original Article Expired nitric oxide levels in adult asthmatics Chiharu Okada, Akihiko Tamaoki, Yasushi Tanimoto, Ryo Soda and Kiyoshi Takahashi National Sanatorium
More informationAnti-allergic Effect of Bee Venom in An Allergic Rhinitis
Anti-allergic Effect of Bee Venom in An Allergic Rhinitis Dr: Magdy I. Al-Shourbagi Sharm International Hospital Allergic Rhinitis Rhinitis: Symptomatic disorder of the nose characterized by itching, nasal
More informationF/P F/P VAS. 2 fexofenadine pseudoefedrine F/P F/P F/P. dust mite HDM 17. fexofenadine pseudoefedrine F/P F/P
JJIAO 35 1 : 1 6, 2017 原 著 / 1 1 2 1 1 3 1 2 3 NPO 2 fexofenadine pseudoefedrine F/P F/P 17 12 5 28.6 F/P F/P VAS F/P 8 30 90 8 2 6 8 F/P F/P, fexofenadine/pseudoephedrine; VAS, visual analogue scale 2
More informationRespiratory Health L O O K, F E E L A N D L I V E B E T T E R
LOOK, FEEL AND LIVE BET TER Respiratory health: hay-fever and asthma Airway obstruction and symptoms in asthma and hay-fever alike are the result of inappropriate responses of the body s immune system
More informationEfficacy of Levocetirizine Compared with Montelukast for the Treatment of Allergic Rhinitis
Human Journals Research Article July 2018 Vol.:10, Issue:1 All rights are reserved by Manju K Mathew et al. Efficacy of Levocetirizine Compared with Montelukast for the Treatment of Allergic Rhinitis Keywords:
More informationAn Update on Allergic Rhinitis. Mike Levin Division of Asthma and Allergy Department of Paediatrics University of Cape Town Red Cross Hospital
An Update on Allergic Rhinitis Mike Levin Division of Asthma and Allergy Department of Paediatrics University of Cape Town Red Cross Hospital Allergic Rhinitis Common condition with increasing prevalence
More informationORIGINAL INVESTIGATION
ORIGINAL INVESTIGATION Superiority of an Intranasal Corticosteroid Compared With an Oral Antihistamine in the As-Needed Treatment of Seasonal Allergic Rhinitis Scott M. Kaszuba, MD; Fuad M. Baroody, MD;
More informationEffect of ramatroban, a thromboxane A 2 antagonist, in the treatment of perennial allergic rhinitis
Allergology International (2003) 52: 131 138 Original Article Effect of ramatroban, a thromboxane A 2 antagonist, in the treatment of perennial allergic rhinitis Kimihiro Ohkubo and Minoru Gotoh Department
More informationImpact of Asthma in the U.S. per Year. Asthma Epidemiology and Pathophysiology. Risk Factors for Asthma. Childhood Asthma Costs of Asthma
American Association for Respiratory Care Asthma Educator Certification Prep Course Asthma Epidemiology and Pathophysiology Robert C. Cohn, MD, FAARC MetroHealth Medical Center Cleveland, OH Impact of
More informationIgE-mediated allergy in elderly patients with asthma
Allergology international (1997) 46: 237-241 Original Article IgE-mediated allergy in elderly patients with asthma Fumihiro Mitsunobu, Takashi Mifune, Yasuhiro Hosaki, Kouzou Ashida, Hirofumi Tsugeno,
More informationClinical Implications of Asthma Phenotypes. Michael Schatz, MD, MS Department of Allergy
Clinical Implications of Asthma Phenotypes Michael Schatz, MD, MS Department of Allergy Definition of Phenotype The observable properties of an organism that are produced by the interaction of the genotype
More informationTherapeutic Effect of Montelukast, a Cysteinyl Leukotriene Receptor 1 Antagonist, on Japanese Patients with Seasonal Allergic Rhinitis
Allergology International. 2008;57:247-255 DOI: 10.2332allergolint.O-07-515 ORIGINAL ARTICLE Therapeutic Effect of Montelukast, a Cysteinyl Leukotriene Receptor 1 Antagonist, on Japanese Patients with
More informationIntroduction. Allergic Rhinitis. Seventh Pediatric Asthma Education Conference 5/9/2018
It Is All One Airway Or How Allergic Rhinitis and Its Management can Affect Asthmatic Patients Stacy Dorris, MD Allergy/Immunology Vanderbilt Medical Center May 9, 2018 Introduction Allergic Rhinitis Allergic
More informationAzelastine nasal spray: the treatment of choice for allergic rhinitis
PRESS RELEASE Azelastine nasal spray: the treatment of choice for allergic rhinitis An astonishing one quarter of the planet s population suffers from allergic rhinitis, living with the aggravating symptoms
More informationTeet Pullerits, MD, PhD, a Lea Praks, MD, PhD, b Vahur Ristioja, MD, c and Jan Lötvall, MD, PhD a Gothenburg, Sweden, and Tartu, Estonia
Comparison of a nasal glucocorticoid, antileukotriene, and a combination of antileukotriene and antihistamine in the treatment of seasonal allergic rhinitis Teet Pullerits, MD, PhD, a Lea Praks, MD, PhD,
More informationAsthma and Vocal Cord Dysfunction
Asthma and Vocal Cord Dysfunction Amy L. Marks DO, FACOP Pediatric Allergy and Immunology Assistant Professor of Pediatrics Oakland University William Beaumont School of Medicine Objectives: Understanding
More informationCase Study. Allergic Rhinitis 5/18/2015
John A. Fling, M.D. Professor Allergy/Immunology University of North Texas Health Science Center, Fort Worth, Texas Case Study 38 year old male with a history of nasal congestion, clear nasal discharge
More informationPathophysiology of the cysteinyl leukotrienes and effects of leukotriene receptor antagonists in asthma
Allergy 2001: 56: Suppl. 66: 7 11 Printed in UK. All rights reserved Copyright # Munksgaard 2001 ALLERGY ISSN 0108-1675 Pathophysiology of the cysteinyl leukotrienes and effects of leukotriene receptor
More informationPharmacotherapy for Allergic Rhinitis
Disclosures: Pharmacotherapy for Allergic Rhinitis None John H. Krouse, MD, PhD, MBA Professor and Chairman Department of Otolaryngology-HNS Temple University School of Medicine Learning Objectives Describe
More informationASTHMA TREATMENT EFFICACY ASSESSMENT BY FeNO MEASUREMENT
Bulletin of the Transilvania University of Braşov Series VI: Medical Sciences Vol. 5 (54) No. 2-2012 ASTHMA TREATMENT EFFICACY ASSESSMENT BY FeNO MEASUREMENT Dana ALEXANDRESCU 1 Abstract: The author of
More informationAllergic Disorders. Allergic Disorders. IgE-dependent Release of Inflammatory Mediators. TH1/TH2 Paradigm
Allergic Disorders Anne-Marie Irani, MD Virginia Commonwealth University Allergic Disorders IgE-mediated immune reactions Clinical entities include: asthma allergic rhinitis atopic dermatitis urticaria
More informationAllergic Disorders. Allergic Disorders. IgE-dependent Release of Inflammatory Mediators. TH1/TH2 Paradigm
Allergic Disorders Anne-Marie Irani, MD Virginia Commonwealth University Allergic Disorders IgE-mediated immune reactions Clinical entities include: asthma allergic rhinitis atopic dermatitis urticaria
More informationStudy on Mechanism of Local Heated Aerosol Therapy in Perennial Allergic Rhinitis
Study on Mechanism of Local Heated Aerosol Therapy in Perennial Allergic Rhinitis Kazuo Sakurai, Kensei Naito, Kenji Takeuchi, Katsuhiko Komori, Hisayuki Kato, Syoji Saito Department of Otolaryngology,
More informationDose-dependent effects of tobramycin in an animal model of Pseudomonas sinusitis Am J Rhino Jul-Aug; 21(4):423-7
AMINOGLYCOSIDES Dose-dependent effects of tobramycin in an animal model of Pseudomonas sinusitis Am J Rhino. 2007 Jul-Aug; 21(4):423-7 http://www.ncbi.nlm.nih.gov/pubmed/17882910 Evaluation of the in-vivo
More informationClinical Study Heart Rate Variability Analysis in Patients with Allergic Rhinitis
The Scientific World Journal Volume 213, Article ID 947385, 4 pages http://dx.doi.org/1.1155/213/947385 Clinical Study Heart Rate Variability Analysis in s with Allergic Rhinitis Ming-Ying Lan, 1,2,3 Guo-She
More informationConcomitant montelukast and loratadine as treatment for seasonal allergic rhinitis: A randomized, placebo-controlled clinical trial
Concomitant montelukast and loratadine as treatment for seasonal allergic rhinitis: A randomized, placebo-controlled clinical trial Eli O. Meltzer, MD, a Kerstin Malmstrom, PhD, b Susan Lu, PharmD, b Bruce
More informationMatt Stumpe, MD Otolaryngologist Mid Kansas Ear, Nose, & Throat
Matt Stumpe, MD Otolaryngologist Mid Kansas Ear, Nose, & Throat Inflammation of the nasal mucosa secondary to an inappropriate hypersensitivity reaction to an allergen IgE mediated immune response with
More informationExhaled Nitric Oxide: An Adjunctive Tool in the Diagnosis and Management of Asthma
Exhaled Nitric Oxide: An Adjunctive Tool in the Diagnosis and Management of Asthma Jason Debley, MD, MPH Assistant Professor, Pediatrics Division of Pulmonary Medicine University of Washington School of
More informationRetrospective Analysis of Patients with Allergy Sinusitis
Original article: Retrospective Analysis of Patients with Allergy Sinusitis G.S. Thalor Senior Specialist (MS) (department of Oto Rhino Laryngology), Govt. S.K. Hospital, Sikar, Rajasthan, India. Corresponding
More informationResearch Institute. Disclosures: Drs Danzig, Yao, and Staudinger are employees of Schering-Plough
A placebo-controlled study of the nasal decongestant effect of phenylephrine and pseudoephedrine in the Vienna Challenge Chamber Friedrich Horak, MD* ; Petra Zieglmayer, MD*; René Zieglmayer, DI ; and
More informationLOOK, FEEL AND LIVE BETTER. Respiratory Health
LOOK, FEEL AND LIVE BETTER Respiratory Health Respiratory health: hay fever and asthma Airway obstruction and symptoms in asthma and hay fever alike are the result of inappropriate responses of the body
More informationInfluence of atopy on exhaled nitric oxide in patients with stable asthma and rhinitis
Eur Respir J 1999; 14: 897±901 Printed in UK ± all rights reserved Copyright #ERS Journals Ltd 1999 European Respiratory Journal ISSN 0903-1936 Influence of atopy on exhaled nitric oxide in patients with
More informationMiddleton Chapter 42b (pages ): Allergic and Nonallergic Rhinitis Prepared by: Tammy Peng, MD
FIT Board Review Corner November 2017 Welcome to the FIT Board Review Corner, prepared by Amar Dixit, MD, and Christin L. Deal, MD, senior and junior representatives of ACAAI's Fellows-In- Training (FITs)
More informationSeasonal Allergic Rhinoconjunctivitis
Seasonal Allergic Rhinoconjunctivitis Allergic rhinoconjunctivitis is a common condition. Most patients can achieve good symptom control through allergen avoidance and pharmacotherapy with non-sedating
More informationSLIT: Review and Update
SLIT: Review and Update Disclosure Speaker: ISTA Pharmaceuticals Speaker: GlaxoSmithKline Allergen IT - Evidence Based Evaluation: Rescue Medications Meta-analysis Disease IT # of Patients Rescue Medication
More informationMolecules, mediators and mechanisms of human allergic reactions
Molecules, mediators and mechanisms of human allergic reactions Bruce S. Bochner, M.D. Samuel M. Feinberg Professor of Medicine Division of Allergy Immunology Northwestern University Feinberg School of
More informationSafety, PK and PD of ARRY-502, a CRTh2 Antagonist, in Healthy Subjects with a History of Seasonal Allergies
Safety, PK and PD of ARRY502, a CRTh2 Antagonist, in Healthy Subjects with a History of Seasonal Allergies L. Burgess*, L. Anderson, C. Nugent, N. Klopfenstein, C. Eberhardt, L. Carter, C. Kass, S. RojasCaro,
More informationPharmacotherapy for Allergic Rhinitis
Pharmacotherapy for Allergic Rhinitis William Reisacher, MD FACS FAAOA Assistant Professor Weill Cornell Medical College The Impact of Allergic Rhinitis Allergic rhinitis affects approximately 50 million
More informationPOSTER PRESENTATIONS
POSTER PRESENTATIONS POSTER PRESENTATIONS The following are summaries of posters presented at the XXI Congress of the European Academy of Allergology and Clinical Immunology, Naples, Italy, June1-5, 2002.
More informationTREATING ALLERGIC RHINITIS
TREATING ALLERGIC RHINITIS Prof. Dr. Jean-Baptiste Watelet, MD Department of Otorhinolaryngology Ghent University Hospital Ghent, Belgium Allergic rhinitis (AR) is a nasal disease with the presence of
More informationXolair (Omalizumab) Drug Prior Authorization Protocol (Medical Benefit & Part B Benefit)
Line of Business: All Lines of Business Effective Date: August 16, 2017 Xolair (Omalizumab) Drug Prior Authorization Protocol (Medical Benefit & Part B Benefit) This policy has been developed through review
More informationEfficacy and safety of montelukast in adults with asthma and allergic rhinitis
Respiratory Medicine (26), 1952 1959 Efficacy and safety of montelukast in adults with asthma and allergic rhinitis J.Chr. Virchow a,, C. Bachert b a Universität Rostock, Ernst-Heydemann-Str. 6, 1857 Rostock,
More informationallergic rhinitis 3C47E65837E D1B E Allergic Rhinitis 1 / 6
Allergic Rhinitis 1 / 6 2 / 6 3 / 6 Allergic Rhinitis Allergic rhinitis is a diagnosis associated with a group of symptoms affecting the nose. These symptoms occur when you breathe in something you are
More informationAllergic rhinitis is the most common
controlled study demonstrated a statistically significant response in those on active therapy. This response was still present 3 years after discontinuing allergy vaccine therapy. 1 Is allergy vaccine
More informationPotent and Selective CRTh2 Antagonists are Efficacious in Models of Asthma, Allergic Rhinitis and Atopic Dermatitis
Potent and Selective CRTh2 Antagonists are Efficacious in Models of Asthma, Allergic Rhinitis and Atopic Dermatitis Laura L. Carter, Yoshi Shiraishi, Yooseob Shin, Laurence Burgess, Christine Eberhardt,
More informationScottish Medicines Consortium
Scottish Medicines Consortium montelukast 10mg tablets (Singulair ) No. (185/05) Merck, Sharp & Dohme Ltd (MSD) New indication: for asthmatic patients in whom montelukast is indicated in asthma, montelukast
More informationTreatment Of Allergic Rhinitis
Treatment Of Allergic Rhinitis 1 / 6 2 / 6 3 / 6 Treatment Of Allergic Rhinitis Galphimia Glauca, Histaminum Hydrochlo-ride, Cardiospermum Halicacabum and Amni Visnaga are effective homeopathic medicines
More informationAllergy and inflammation
and inflammation 1 Allergic population hyper-producers of IgE consistently increasing western societies: ~20% of general population 2 Allergic population 3 Allergic triggers 4 Allergic triggers abnormal
More informationScottish Medicines Consortium
Scottish Medicines Consortium Standardised allergen extract of grass pollen from Timothy (Phleum pratense) 75,000 SQ-T per oral lyophilisate (Grazax ) No. (367/07) ALK-Abellό Ltd 6 April 2007 The Scottish
More informationLeukotriene C 4 synthase polymorphisms and responsiveness to leukotriene antagonists in asthma
Blackwell Science, LtdOxford, UKBCPBritish Journal of Clinical Pharmacology0306-5251Blackwell Publishing 2003? 2003564422426Original ArticleLeukotriene C4 synthasej. J. Lima et al. Leukotriene C 4 synthase
More informationDoes rhinitis. lead to asthma? Does sneezing lead to wheezing? What allergic patients should know about the link between allergic rhinitis and asthma
Does rhinitis lead to asthma? Does sneezing lead to wheezing? What allergic patients should know about the link between allergic rhinitis and asthma For a better management of allergies in Europe Allergy
More informationEarly and late allergic reaction in the nose assessed by whole body plethysmography
Eur Respir J, 1996, 9, 1701 1706 DOI: 10.1183/09031936.96.09081701 Printed in UK - all rights reserved Copyright ERS Journals Ltd 1996 European Respiratory Journal ISSN 0903-1936 Early and late allergic
More informationDisclosures. Learning Objective. Biological therapies. Biologics with action against 11/30/2011. Biologic Asthma Therapies and Individualized Medicine
Biologic Asthma Therapies and Individualized Medicine Mark S. Dykewicz, MD Director, Allergy & Immunology Fellowship Program Director Wake Forest University School of Medicine Winston-Salem, North Carolina
More informationIdentifying Biologic Targets to Attenuate or Eliminate Asthma Exacerbations
Identifying Biologic Targets to Attenuate or Eliminate Exacerbations exacerbations are a major cause of disease morbidity and costs. For both children and adults, viral respiratory infections are the major
More informationCLINICAL POLICIES FORUM
Date of Meeting: 10 September 2013 CLINICAL POLICIES FORUM For: Note: To note Edits to Allergic Rhinitis Primary Care Pathway to reflect change in treatment group over 12 year olds Changes to text within
More informationWorld Health Organisation Initiative. Allergic rhinitis and its impact on asthma. (ARIA). Bousquet J, van Cauwenberge P. Geneva: WHO;2000.
Glenis Scadding Infectious Viral Bacterial Other infective agents Allergic Intermittent Persistent Occupational (allergic/non-allergic) Intermittent Persistent Drug-induced Aspirin Other medications Hormonal
More informationAs-needed use of fluticasone propionate nasal spray reduces symptoms of seasonal allergic rhinitis
As-needed use of fluticasone propionate nasal spray reduces symptoms of seasonal allergic rhinitis Albert Jen, MD, Fuad Baroody, MD, Marcy detineo, BSN, Lauran Haney, BSc, Christopher Blair, BSc, and Robert
More informationIASIAN PACIFIC JOURNAL OF ALLERGY AND IMMUNOLOGY (2001) 19:
IASIAN PACIFIC JOURNAL OF ALLERGY AND IMMUNOLOGY (2001) 19: 171-175 A Double-Blind, Placebo-Controlled, and Randomized Study of Loratadine (Clarityne) Syrup for the Treatment of Allergic Rhinitis in Children
More informationMonocast Description Indications
Monocast Tablet Description The active ingredient of Monocast tablet is Montelukast Sodium INN. Montelukast is a selective and orally active leukotriene receptor antagonist that inhibits the cysteinyl
More informationEar, Nose & Throat (ENT) - Head & Neck Surgery. Allergic Rhinitis (Sinus)
Ear, Nose & Throat (ENT) - Head & Neck Surgery Allergic Rhinitis (Sinus) The Department of Ear, Nose & Throat (ENT) - Head & Neck Surgery provides a wide range of surgical services for adult patients with
More informationAcquiring the population sample: confirmation of the diagnosis. GENERAL ASPECTS OF CLINICAL TRIAL DESIGN FOR RHINITIS Patient populations
Clinical trial design, nasal allergen challenge models, and considerations of relevance to pediatrics, nasal polyposis, and different classes of medication Anders Akerlund, MD, PhD, a Morgan Andersson,
More informationGlossary of Asthma Terms
HealthyKidsExpress@bjc.org Asthma Words to Know Developed in partnership with Health Literacy Missouri Airways (Bronchi, Bronchial Tubes): The tubes in the lungs that let air in and out of the body. Airway
More informationClinical and Experimental Allergy
ORIGINAL PAPER Clinical and Experimental Allergy, 36, 26 31 c 2006 Blackwell Publishing Ltd Stronger nasal responsiveness to cold air in individuals with rhinitis and asthma, compared with rhinitis alone
More informationObservational study of tympanic membrane changes in allergic rhinitis
International Journal of Research in Medical Sciences Katiyar VMH et al. Int J Res Med Sci. 2016 Sep;4(9):3977-3981 www.msjonline.org pissn 2320-6071 eissn 2320-6012 Research Article DOI: http://dx.doi.org/10.18203/2320-6012.ijrms20162918
More informationImmunology of Asthma. Kenneth J. Goodrum,Ph. Ph.D. Ohio University College of Osteopathic Medicine
Immunology of Asthma Kenneth J. Goodrum,Ph Ph.D. Ohio University College of Osteopathic Medicine Outline Consensus characteristics/incidence data Immune/inflammatory basis Etiology/Genetic basis Hygiene
More informationRepeated antigen challenge in patients with perennial allergic rhinitis to house dust mites
Allergology International (2003) 52: 207 212 Original Article Repeated antigen challenge in patients with perennial allergic rhinitis to house dust mites Minoru Gotoh, Kimihiro Okubo and Minoru Okuda Department
More informationDistinction and Overlap. Allergy Dpt, 2 nd Pediatric Clinic, University of Athens
Asthma Phenotypes: Distinction and Overlap Nikos Papadopoulos Allergy Dpt, 2 nd Pediatric Clinic, University of Athens Asthma as a syndrome From the Iliad to ADAM 33 and back again Bronchoconstriction,
More informationORIGINAL ARTICLE. Increased Nasal Airflow With Budesonide Compared With Desloratadine During the Allergy Season
ORIGINAL ARTICLE Increased Nasal Airflow With Budesonide Compared With Desloratadine During the Allergy Season Sandeep Bhatia, BS; Fuad M. Baroody, MD; Marcy detineo, BSN; Robert M. Naclerio, MD Objective:
More informationAdenosine 5 0 -monophosphate increases levels of leukotrienes in breath condensate in asthma
Respiratory Medicine (2004) 98, 651 655 Adenosine 5 0 -monophosphate increases levels of leukotrienes in breath condensate in asthma E. Bucchioni, Z. Csoma, L. Allegra, K.F. Chung, P.J. Barnes, S.A. Kharitonov*
More informationAllergic Rhinitis and Its Impact on Ast. Rhinitis: A Risk Factor for Asthma? Ronald Dahl, Aarhus University Hospital, Denmark
Allergic Rhinitis and Its Impact on Ast Rhinitis: A Risk Factor for Asthma? Ronald Dahl, Aarhus University Hospital, Denmark Rhinitis and asthma SIT-SLIT Evidence A SIT-SLIT Evidence A? SIT Evidence? Rhinitis
More informationMontelukast in the management of allergic rhinitis
REVIEWS Montelukast in the management of allergic rhinitis Jaime A Lagos Gailen D Marshall Division of Clinical Immunology and Allergy, University of Mississippi Medical Center, Jackson, MS, USA Abstract:
More informationClinical Medicine Reviews in Therapeutics. A Review of Rupatadine in the Treatment of Seasonal Allergic Rhinitis. R. Borici-Mazi.
Clinical Medicine Reviews in Therapeutics ExpERT REviEw A Review of Rupatadine in the Treatment of Seasonal Allergic Rhinitis R. Borici-Mazi Medicine and pediatrics, Division of Allergy and immunology,
More informationComparative Study of Nasal Smear and Biopsy in Patients of Allergic Rhinitis
Indian J Allergy Asthma Immunol 2002; 16(1) : 27-31 Comparative Study of Nasal Smear and Biopsy in Patients of Allergic Rhinitis Rakesh Chanda, Ajay Kumar Aggarwal, G.S. Kohli, T.S. Jaswal*, and K.B. Gupta**
More informationNATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE INTERVENTIONAL PROCEDURES PROGRAMME Interventional procedure overview of intranasal phototherapy for allergic rhinitis Allergic rhinitis is inflammation
More informationAn update on childhood sleep-disordered breathing
An update on childhood sleep-disordered breathing แพทย หญ งวนพร อน นตเสร ภาคว ชาก มารเวชศาสตร คณะแพทยศาสตร มหาว ทยาล ยสงขลานคร นทร Sleep-disordered breathing Primary snoring Upper airway resistance syndrome
More informationAllergies and Asthma 5/21/2013. Objectives. Allergic Rhinitis (AR): Risk Factor for ASTHMA. Rhinitis and Asthma
Allergies and Asthma Presented By: Dr. Fadwa Gillanders, Pharm.D Clinical Pharmacy Specialist May 2013 Objectives Understand the relationship between asthma and allergic rhinitis Understand what is going
More informationI have no perceived conflicts of interest or commercial relationships to disclose.
ASTHMA BASICS Michelle Dickens RN FNP-C AE-C Nurse Practitioner/Certified Asthma Educator Ferrell Duncan Allergy/Asthma/Immunology Coordinator, CoxHealth Asthma Center DISCLOSURES I have no perceived conflicts
More informationAge-related changes of IgE-mediated allergic reaction in patients with late onset asthma.
50 Changes in IgE-mediated allergic reaction with aglllg Age-related changes of IgE-mediated allergic reaction in patients with late onset asthma. Fumihiro Mitsunobu, Takashi Mifune, Yasuhiro Hosaki, Kouzou
More informationDr ARIF AHMED M.D.(Paed.), D.Ch., M.D.(USA), European Board (EACCI) Certified in Allergy & Immunology
Case Based Approach to Allergic Unified Airway Diseases Dr ARIF AHMED M.D.(Paed.), D.Ch., M.D.(USA), European Board (EACCI) Certified in Allergy & Immunology Recent Advances in Pediatrics 23: Hot Topics
More informationImmunomodulators: Anti-IgE mab. Thomas B. Casale, MD Professor of Medicine Chief, Allergy/Immunology Creighton University Omaha, NE
Immunomodulators: Anti-IgE mab Thomas B. Casale, MD Professor of Medicine Chief, Allergy/Immunology Creighton University Omaha, NE Objectives To explain the rationale behind IgE blockade To discuss which
More informationManaging and Treating Allergic Rhinitis in the Primary Care Setting
University of Vermont ScholarWorks @ UVM Family Medicine Block Clerkship, Student Projects College of Medicine 2014 Managing and Treating Allergic Rhinitis in the Primary Care Setting Leah Novinger University
More informationALLERGIC RHINOSINUSITIS. Sirisha A Post graduate Dept of Pharmacology Kamineni Institute of Medical Sciences
ALLERGIC RHINOSINUSITIS Sirisha A Post graduate Dept of Pharmacology Kamineni Institute of Medical Sciences OVERVIEW Pathophysiology Goals of therapy Approaches to therapy Antihistaminics Corticosteroids
More informationSilymarin effect on persistent allergic Rhinitis. Bakhshaee M, MD Rhinologist Assistant Prof. of MUMS
Silymarin effect on persistent allergic Rhinitis Bakhshaee M, MD Rhinologist Assistant Prof. of MUMS Introduction In the wide range of allergic diseases, allergic rhinitis with a 20% prevalence rate is
More informationThe role of antihistamines in upper respiratory tract infections
The role of antihistamines in upper respiratory tract infections Robert C. Welliver, MD Buffalo, N.Y. Antihistamines are commonly administered for URI, but their efficacy cannot be easily demonstrated.
More informationasthma, order-made medicine, phenotypes 2.1 Cluster analysis by Haldar et al.
Received: 8 June 2015 Accepted: 25 February 2016 DOI: 10.1002/jgf2.7 REVIEW ARTICLE Asthma phenotypes Masahiro Hirose MD, PhD Takahiko Horiguchi MD, PhD Department of Respiratory Medicine II, Fujita Health
More informationA clinical trial of ipratropium bromide nasal spray in patients with perennial nonallergic rhinitis
A clinical trial of ipratropium bromide nasal spray in patients with perennial nonallergic rhinitis Edwin A. Bronsky, MD, Howard Druce, MD, Steven R. Findlay, MD, Frank C. Hampel, MD, Harold Kaiser, MD,
More informationCOPD and Asthma: Similarities and differences Prof. Peter Barnes
and Asthma: Similarities and Differences and Asthma: 1 Imperial College Peter Barnes FRS, FMedSci, National Heart & Lung Institute Imperial College, London, UK p.j.barnes@imperial.ac.uk Royal Brompton
More informationAllergic rhinitis and the united airway in asthma
Earn 3 CPD Points online Allergic rhinitis and the united airway in asthma Based on a presentation by Dr Todd Marr Director: Paediatric Allergy/ Immunology Gunderson Lutheran Medical Centre La Crosse,
More information